Aim Several biomarkers are currently used as diagnostic and prognostic tools in patients with cancer. Soluble urokinase plasminogen activator receptor (suPAR) is elevated in acute and chronic inflammatory procedures and several observational studies during the last 20 years have investigated its role in oncology. The purpose of this article was to ...

By Themistoklis Paraskevas, Francesk Mulita, Christos Michailides, Georgios-Ioannis Verras, Elias Liolis, Eleousa Oikonomou, Ioannis Perdikaris, Panagiotis Perdikaris, Konstantinos Bouchagier, Ioannis Panagiotopoulos, Dimitrios-Ioannis Kasartzian, Dimitrios Filis, Levan Tchabashvili, Despoina Spyropoulou, Dimitrios Velissaris